Search

Your search keyword '"Gyorki, David E."' showing total 363 results

Search Constraints

Start Over You searched for: Author "Gyorki, David E." Remove constraint Author: "Gyorki, David E."
363 results on '"Gyorki, David E."'

Search Results

2. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

5. What is the association of preoperative biopsy with recurrence and survival in retroperitoneal sarcoma? A systematic review by the Australia and New Zealand Sarcoma Association clinical practice guidelines working party

9. Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group

11. Contributors

13. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

15. A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases.

16. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

18. International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers

19. Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis

20. Case report: Partial regression of metastatic squamous cell carcinoma with altered azathioprine dosage after long-term use in renal transplant patient.

21. Update of clinical practice guidelines for the management of patients with sarcoma.

24. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

26. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

27. CD4 + T cell immunity against cutaneous melanoma encompasses multifaceted MHC II–dependent responses

28. Clinical activity in general practice before sarcoma diagnosis: an Australian cohort study.

35. Systemic Therapy for Melanoma: ASCO Guideline Update

36. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis

46. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection

47. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study

48. NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.

49. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma:Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

Catalog

Books, media, physical & digital resources